Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
In this medfyle
Pooled analysis shows positive benefit–risk profile.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in the Lupus Science & Medicine, EULAR’s official journal, through an official agreement with BMJ.
The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by Ronald F. van Vollenhoven, MD, PhD, Amsterdam UMC and Amsterdam Rheumatology Center, Amsterdam, the Netherlands.
Original article:
Tummala R, Abreu G, Pineda L, et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Science & Medicine 2021;8:e000464. doi: 10.1136/lupus-2020-000464
The authors of the original article had no part in the creation of the summary.
Copyright © 2020 BMJ Publishing Group Limited and Globalport (International) Limited. All rights reserved.
The summaries, expert commentaries and slides included in this Medfyle are co-owned by BMJ and GlobalPort (International) Limited. The original journal article is an exclusive copyright of BMJ Publishing Group Limited.
